Search
Paritaprevir
go.drugbank.com/drugs/DB09297ApprovedInvestigationalParitaprevir is also available as a fixed-dose combination product with [DB09296] and [DB00503] as the FDA- and Health Canada-approved product Technivie. … Paritaprevir is a direct acting antiviral medication used as part of combination therapy to treat chronic Hepatitis C, an infectious liver disease caused by infection with Hepatitis C Virus (HCV).
Mixtures: VIEKIRAX 12.5 MG/75 MG/50 MG FILM KAPLI TABLET ,56 TABLETCategories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesRindopepimut
go.drugbank.com/drugs/DB05374InvestigationalRindopepimut (CDX-110) is an injectable peptide cancer vaccine which targets a mutant protein called EGFRvIII present in about 25% to 30% of glioblastoma cases. … The vaccine consists of the EGFRv3-specific peptide (a 13-amino acid mutant vIII epitope) conjugated to the non-specific immunomodulator keyhole limpet hemocyanin (KLH).
Polysorbate 80
go.drugbank.com/drugs/DB11063ApprovedInvestigationalPolysorbate, a substance formulated by the reaction of sorbitan fatty acid ester (a nonionic surfactant) with ethylene oxide, is used in many foreign countries, including the U.S. and the EU, where it … Polysorbate 80 is a hydrophilic nonionic surfactant. It is utilized as a surfactant in soaps and cosmetics and also as a lubricant in eye drops.
Mixtures: ENDURA® UDCategories: Compounds used in a research, industrial, or household setting, Cytochrome P-450 CYP3A InhibitorsEtorphine
go.drugbank.com/drugs/DB01497ExperimentalIllicitVet approvedA narcotic analgesic morphinan used as a sedative in veterinary practice. … Etorphine is only available to the patients under an official prescription. In the US, Etorphine is listed as a Schedule I drug, although Etorphine hydrochloride is classified as Schedule II.
Delorazepam
go.drugbank.com/drugs/DB01511IllicitInvestigationalIn addition to be long acting, delorazepam is relatively potent, with 1 mg of delorazepam being the equivalent of 10 mg diazepam. It has been approved for marketing in Italy. … It may have adverse effects such as drowsiness, and cognitive impairments such as short term memory impairment. Delorazepam is an active metabolite of the benzodiazepine known as cloxazolam.
International brands: Delorazepam EGProducts: DELORAZEPAM EGPhenacetin
go.drugbank.com/drugs/DB03783ApprovedWithdrawnPhenacetin was withdrawn from the Canadian market in June 1973 due to concerns regarding nephropathy (damage to or disease of the kidney).
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A1 SubstratesMevastatin
go.drugbank.com/drugs/DB06693ExperimentalMevastatin is a competitive inhibitor of HMG-Coenzyme A (HMG-CoA) reductase with a binding affinity 10,000 times greater than the HMG-CoA substrate itself. … Two years later, the research group isolated a compound structurally similar to hydroxymethylglutarate (HMG) that inhibited the incorporation of acetate.
Pradefovir mesylate
go.drugbank.com/drugs/DB05478InvestigationalPradefovir mesilate (previously known as MB-06886, Hepavir B and remofovir mesylate) is an orally administered small molecule compound that belongs to a novel series of phosphate and phosphonate prodrugs … Pradefovir is activated through oxidation that is mediated by cytochrome P-450 (CYP) 3A4, which is predominantly expressed in the liver.
Tivozanib
go.drugbank.com/drugs/DB11800ApprovedInvestigationalIt was approved on March 10, 2021 by the FDA. Marketed by Aveo Oncology, tivozanib is a promising therapy for individuals with RCC who have not been treated successfully with other therapies.[L32524] … [L32529] Tivozanib, also known as FOTIVDA, is a kinase inhibitor developed to treat adult patients with relapsed or refractory advanced renal cell carcinoma (RCC) after prior failed systemic therapies
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesDostarlimab
go.drugbank.com/drugs/DB15627ApprovedInvestigational[L33340] This indication was granted full FDA approval on February 10, 2023.[L45161] Dostarlimab-gxly was granted second accelerated approval for the treatment of solid tumours in the same month. … A prospective phase II study in patients with mismatch repair-deficient locally advanced rectal cancer resulted in all twelve patients exhibiting a complete clinical response.[A248905]